Nova Southeastern University Office of Academic Affairs Search NSU Site Map Nova Southeastern University
President's Faculty R & D Grant 
Committees, Councils
  and Boards
Faculty Policy Manual
NSU Scholarly Journals
Professional Journals
Prof. Memberships
Academic Policies & Procedures
Provost's Research and Scholarship Award
President's Faculty
 R & D Grant
PFRDG Application Review Process by NSU Librarians
Office of Academic Quality, Assessment, and Accreditation
Contact Us

Print this page  


With a focus on learning, we employ a range of strategies to support innovation, collaboration across centers, and university-wide discussion and decision-making


Fourth Annual Grant Winners 2003-2004

Ruth E. Nemire, Pharm. D., HPD College of Pharmacy
Michelle T. Assa-Eley, Ph.D., HPD College of Pharmacy
R. Eugene Ramsay, M.D., University of Miami -College of Medicine

Dean William Hardigan – HPD College of Pharmacy

Title: Osteoporosis in Men Ages 40-65 Taking Anticonvulsant Medication


Osteoporosis is rapidly becoming a public health concern. As the population ages, more individuals both men and women are being diagnosed with osteoporosis. Fractures cost the health care system billions of dollars annually. Elderly patients with fractures have a higher morbidity and mortality than those who do not. Patients with Epilepsy may be at an increased risk, due to the nature of the antiepileptic drugs. Agents such as Dilantin, phenobarbital or carbamazepine are enzyme inducing agents and may increase the clearance of Vitamin D. This causes a higher risk in these patients for developing osteopenia, osteoporosis and fracture. While there are some studies in men with osteoporosis, few focus on men with epilepsy. This study will enroll thirty men between the ages of 40-65 who are taking one enzyme inducing agent and who do not have multiple risk factors. They will be asked to complete a questionnaire to determine risk, and will receive a DEXA bone scan to determine their bone health. Patients with or without osteopenia will be randomly placed in one of two groups and followed for a year. Patients with osteoporosis will be referred to their primary care physician for care. At the end of a year, a repeat DEXA scan will be completed to assess change. All patients will be asked to sign consent and will be receiving a standard of care, which is not currently exercised in the treatment of epilepsy. The outcome of this study may determine a new standard with regard to bone health for patients with epilepsy.